Erratum: "A phase I/II clinical trial in localized prostate cancer of an adenovirus expressing nitroreductase with CB1984" (Molecular Therapy (2009) vol. 17 (1292-1299) 10.1038/mt.2009.80);A phase I/II clinical trial in localized prostate cancer of an adenovirus expressing nitroreductase with CB1984

Molecular Therapy

Volumn 17, Issue 7, 2009, Pages 1292-1299

  Patel, Prashant ^a   Young, J Graham ^a   Mautner, Vivien ^a   Ashdown, Daniel ^a   Bonney, Sarah ^a   Pineda, Robert G ^a   Collins, Stuart I ^a   Searle, Peter F ^a   Hull, Diana ^b   Peers, Elizabeth ^c   Chester, John ^d   Wallace, D Michael ^b   Doherty, Alan ^b   Leung, Hing ^e   Young, Lawrence S ^a   James, Nicholas D ^a  

^a UNIVERSITY OF BIRMINGHAM   (United Kingdom)

^b QUEEN ELIZABETH HOSPITAL   (United Kingdom)

^c Innovata PLC   (United Kingdom)

^d ST JAMES S UNIVERSITY HOSPITAL   (United Kingdom)

^e NEWCASTLE UNIVERSITY   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

5 (1 AZIRIDINYL) 2,4 DINITROBENZAMIDE; ADENOVIRUS VECTOR; NITROREDUCTASE; PROSTATE SPECIFIC ANTIGEN;

ADULT; AGED; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ALKALINE PHOSPHATASE BLOOD LEVEL; AMNESIA; ANTIBODY RESPONSE; ARTICLE; BILIRUBIN BLOOD LEVEL; CANCER SURVIVAL; CLINICAL ARTICLE; CLINICAL TRIAL; CONTINUOUS INFUSION; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIARRHEA; DOSE RESPONSE; DRUG BLOOD LEVEL; DRUG DOSE ESCALATION; DRUG FEVER; DRUG HALF LIFE; DRUG RESPONSE; DRUG SAFETY; DRUG TOLERABILITY; GENE DIRECTED ENZYME PRODRUG THERAPY; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; LETHARGY; LYMPHOCYTOPENIA; MALE; MULTIPLE CYCLE TREATMENT; NAUSEA; PHASE 1 CLINICAL TRIAL; PHASE 2 CLINICAL TRIAL; PREOPERATIVE CARE; PROSTATE CANCER; PROSTATE EPITHELIUM; PROSTATECTOMY; RETREATMENT; SIDE EFFECT; SINGLE DRUG DOSE; SURVIVAL TIME; VIRUS PARTICLE;

ADENOVIRIDAE; BACTERIA (MICROORGANISMS);

ADENOVIRIDAE; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC AGENTS; AZIRIDINES; GENE THERAPY; GENETIC VECTORS; HUMANS; MALE; MIDDLE AGED; NITROREDUCTASES; PRODRUGS; PROSTATIC NEOPLASMS;

EID: 67649872626     PISSN: 15250016     EISSN: 15250024     Source Type: Journal    
DOI: 10.1038/mt.2009.110     Document Type: Erratum

References (34)

1. Parkin, DM, Bray, F, Ferlay, J and Pisani, P (2001). Estimating the world cancer burden: Globocan 2000. Int J Cancer 94: 153-156.
2. Garnick, MB and Fair, WR (1996). Prostate cancer: Emerging concepts. Part I. Ann Intern Med 125: 118-125.
3. Moul, JW (2000). Prostate specific antigen only progression of prostate cancer. J Urol 163: 1632-1642.
4. Han, M, Partin, AW, Pound, CR, Epstein, JI and Walsh, PC (2001). Long-term biochemical disease-free and cancer-specific survival following anatomic radical retropubic prostatectomy. The 15-year Johns Hopkins experience. Urol Clin North Am 28: 555-565.
5. Jemal, A, Siegel, R, Ward, E, Murray, T, Xu, J, Smigal, C et al. (2006). Cancer statistics, 2006. CA Cancer J Clin 56: 106-130.
6. Journal of Gene Medicine (2006). Gene Therapy Clinical Trials Worldwide: Update 09/2006 .
7. Weedon, SJ, Green, NK, McNeish, IA, Gilligan, MG, Mautner, V, Wrighton, CJ et al. (2000). Sensitisation of human carcinoma cells to the prodrug CB1954 by adenovirus vector-mediated expression of E. coli nitroreductase. Int J Cancer 86: 848-854.
8. Djeha, AH, Thomson, TA, Leung, H, Searle, PF, Young, LS, Kerr, DJ et al. (2001). Combined adenovirus-mediated nitroreductase gene delivery and CB1954 treatment: A well-tolerated therapy for established solid tumors. Mol Ther 3: 233-240.
9. Palmer, DH, Mautner, V, Mirza, D, Oliff, S, Gerritsen, W, van der Sijp, JR et al. (2004). Virus-directed enzyme prodrug therapy: intratumoral administration of a replication-deficient adenovirus encoding nitroreductase to patients with resectable liver cancer. J Clin Oncol 22: 1546-1552.
10. Anlezark, GM, Melton, RG, Sherwood, RF, Coles, B, Friedlos, F and Knox, RJ (1992). The bioactivation of 5-(aziridin-1-yl)-2,4-dinitrobenzamide (CB1954) - I. Purification and properties of a nitroreductase enzyme from Escherichia coli - a potential enzyme for antibody-directed enzyme prodrug therapy (ADEPT). Biochem Pharmacol 44: 2289-2295.
11. Friedlos, F, Quinn, J, Knox, RJ and Roberts, JJ (1992). The properties of total adducts and interstrand crosslinks in the DNA of cells treated with CB 1954. Exceptional frequency and stability of the crosslink. Biochem Pharmacol 43: 1249-1254.
12. Grove, JI, Searle, PF, Weedon, SJ, Green, NK, McNeish, IA and Kerr, DJ (1999). Virus-directed enzyme prodrug therapy using CB1954. Anticancer Drug Des 14: 461-472.
13. Bridgewater, JA, Knox, RJ, Pitts, JD, Collins, MK and Springer, CJ (1997). The bystander effect of the nitroreductase/CB1954 enzyme/prodrug system is due to a cell-permeable metabolite. Hum Gene Ther 8 709-717.
14. Djeha, AH, Hulme, A, Dexter, MT, Mountain, A, Young, LS, Searle, PF et al. (2000). Expression of Escherichia coli B nitroreductase in established human tumor xenografts in mice results in potent antitumoral and bystander effects upon systemic administration of the prodrug CB1954. Cancer Gene Ther 7: 721-731.
15. Chung-Faye, G, Palmer, D, Anderson, D, Clark, J, Downes, M, Baddeley, J et al. (2001). Virus-directed, enzyme prodrug therapy with nitroimidazole reductase: A phase I and pharmacokinetic study of its prodrug, CB1954. Clin Cancer Res 7: 2662-2668.
16. Herman, JR, Adler, HL, Aguilar-Cordova, E, Rojas-Martinez, A, Woo, S, Timme, TL et al. (1999). In situ gene therapy for adenocarcinoma of the prostate: A phase I clinical trial. Hum Gene Ther 10: 1239-1249.
17. DeWeese, TL, van der Poel, H, Li, S, Mikhak, B, Drew, R, Goemann, M et al. (2001). A phase I trial of CV706, a replication-competent, PSA selective oncolytic adenovirus, for the treatment of locally recurrent prostate cancer following radiation therapy. Cancer Res 61: 7464-7472.
18. Merritt, JA, Roth, JA and Logothetis, CJ (2001). Clinical evaluation of adenoviral-mediated p53 gene transfer: Review of INGN 201 studies. Semin Oncol 28 (5 Suppl 16): 105-114.
19. Teh, BS, Ayala, G, Aguilar, L, Mai, WY, Timme, TL, Vlachaki, MT et al. (2004). Phase I-II trial evaluating combined intensity-modulated radiotherapy and in situ gene therapy with or without hormonal therapy in treatment of prostate cancer-interim report on PSA response and biopsy data. Int J Radiat Oncol Biol Phys 58: 1520-1529.
20. Dilley, J, Reddy, S, Ko, D, Nguyen, N, Rojas, G, Working, P et al. (2005). Oncolytic adenovirus CG7870 in combination with radiation demonstrates synergistic enhancements of antitumor efficacy without loss of specificity. Cancer Gene Ther 12: 715-722.
21. van der Linden, RR, Haagmans, BL, Mongiat-Artus, P, van Doornum, GJ, Kraaij, R, Kadmon, D et al. (2005). Virus specific immune responses after human neoadjuvant adenovirus-mediated suicide gene therapy for prostate cancer. Eur Urol 48: 153-161.
22. Tetzlaff, MT, Teh, BS, Timme, TL, Fujita, T, Satoh, T, Tabata, K et al. (2006). Expanding the therapeutic index of radiation therapy by combining in situ gene therapy in the treatment of prostate cancer. Technol Cancer Res Treat 5: 23-36.
23. Pisters, LL, Pettaway, CA, Troncoso, P, McDonnell, TJ, Stephens, LC, Wood, CG et al. (2004). Evidence that transfer of functional p53 protein results in increased apoptosis in prostate cancer. Clin Cancer Res 10: 2587-2593.
24. Shalev, M, Kadmon, D, Teh, BS, Butler, EB, Aguilar-Cordova, E, Thompson, TC et al. (2000). Suicide gene therapy toxicity after multiple and repeat injections in patients with localized prostate cancer. J Urol 163: 1747-1750.
25. Freytag, SO, Khil, M, Stricker, H, Peabody, J, Menon, M, DePeralta-Venturina, M et al. (2002). Phase I study of replication-competent adenovirus-mediated double suicide gene therapy for the treatment of locally recurrent prostate cancer. Cancer Res 62: 4968-4976.
26. Ayala, G, Satoh, T, Li, R, Shalev, M, Gdor, Y, Aguilar-Cordova, E et al. (2006). Biological response determinants in HSV-tk + ganciclovir gene therapy for prostate cancer. Mol Ther 13: 716-728.
27. Scher, HI, Eisenberger, M, D'Amico, AV, Halabi, S, Small, EJ, Morris, M et al. (2004). Eligibility and outcomes reporting guidelines for clinical trials for patients in the state of a rising prostate-specific antigen: Recommendations from the Prostate-Specific Antigen Working Group. J Clin Oncol 22: 537-556.
28. Grove, JI, Lovering, AL, Guise, C, Race, PR, Wrighton, CJ, White, SA et al. (2003). Generation of Escherichia coli nitroreductase mutants conferring improved cell sensitization to the prodrug CB1954. Cancer Res 63: 5532-5537.
29. Hu, L, Yu, C, Jiang, Y, Han, J, Li, Z, Browne, P et al. (2003). Nitroaryl phosphoramides as novel prodrugs for E. coli nitroreductase activation in enzyme prodrug therapy. J Med Chem 46: 4818-4821.
30. Green, NK, McNeish, IA, Doshi, R, Searle, PF, Kerr, DJ and Young, LS (2003). Immune enhancement of nitroreductase-induced cytotoxicity: studies using a bicistronic adenovirus vector. Int J Cancer 104 104-112.
31. Anderson, D, Ferry, DR, Knox, RJ, Andrews, SJ, Downes, AJ, Kerr, DJ et al. (1999). High-performance liquid chromatographic method for sensitive determination of the alkylating agent CB1954 in human plasma. J Chromatogr B Biomed Sci Appl 731: 293-298.
32. Stallwood, Y, Fisher, KD, Gallimore, PH and Mautner, V (2000). Neutralisation of adenovirus infectivity by ascitic fluid from ovarian cancer patients. Gene Ther 7: 637-643.
33. Cannon, GM Jr., Walsh, PC, Partin, AW and Pound, CR (2003). Prostate-specific antigen doubling time in the identification of patients at risk for progression after treatment and biochemical recurrence for prostate cancer. Urology 62 (Suppl 1):2-8.
34. Turnbull, BW (1976). The empirical distribution function with arbitrarily grouped, censored and truncated data. J R Stat Soc 38: 290-295.